Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
Brigham and Women's Hospital
MedSIR
MedSIR
Hoffmann-La Roche
Stanford University
Mayo Clinic
University of Rochester
University of Washington
City of Hope Medical Center
Beijing Biostar Pharmaceuticals Co., Ltd.
MedSIR
Biogen
Guangzhou Medical University
Stanford University
Tongji Hospital
Fudan University
National Cancer Institute (NCI)
Seagen Inc.
Hoffmann-La Roche
Fudan University
Sun Yat-sen University
Jules Bordet Institute
US Oncology Research
Dana-Farber Cancer Institute
National Taiwan University Hospital
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
DEKK-TEC, Inc.
Case Comprehensive Cancer Center
Institut Paoli-Calmettes
Angiochem Inc
Cambridge University Hospitals NHS Foundation Trust
Novartis
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Fudan University
City of Hope Medical Center
ChineseAMS
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
University of California, San Francisco
AIO-Studien-gGmbH
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
University of Washington
Merck Sharp & Dohme LLC
Fred Hutchinson Cancer Center
Alliance for Clinical Trials in Oncology